**Supplemental materials**

**Supplemental Figure 1.** CD66b and HE were both measured by the slideToolkit method.Univariable association of CD66b and HE with gender. **A.** The total number of CD66b positive cells (inverse rank transformed) was significantly higher in male patients in contrast with female patients (p<0.001). **B.** The total number of nuclei (positive HE staining)was significantly higher in male patients in comparison with female patients (p<0.001)



**Supplemental Table 1.** Percentage of participant with missing values.

|  |  |  |
| --- | --- | --- |
|  | **Percentage of participants with missing values before multivariate imputation by chained equations (%)** | **Percentage of participants with missing values after multivariate imputation by chained equations (%)** |
| Hospital | 0.0 | 0.0 |
| Age | 0.0 | 0.0 |
| Gender | 0.0 | 0.0 |
| Systolic BP | 13.3 | 2.8 |
| Diastolic BP | 13.4 | 2.8 |
| Hypertension | 2.2 | 2.2 |
| Diabetes mellitus | 0.0 | 0.0 |
| Hypercholesterolemia | 7.4 | 7.4 |
| Total cholesterol | 38.7 | 5.2 |
| HDL | 45.4 | 5.9 |
| LDL | 42.2 | 5.8 |
| Triglycerides | 41.9 | 5.7 |
| BMI | 3.7 | 3.7 |
| eGFR | 5.1 | 0.5 |
| Smoking Status | 4.7 | 2.6 |
| History of coronary artery disease | 0.1 | 0.1 |
| History of peripheral artery disease | 0.3 | 0.3 |
| History of peripheral intervention(s) | 0.3 | 0.3 |
| History of stroke or TIA | 0.0 | 0.0 |
| Use of antihypertensive drugs | 0.2 | 0.2 |
| Use of statins | 0.2 | 0.2 |
| Use of antiplatelet drugs | 0.4 | 0.4 |
| Use of oral anticoagulant drugs | 0.2 | 0.2 |
| Ipsilateral pre-operative stenosis | 2.4 | 0.3 |
| Contralateral stenosis | 10.6 | 1.6 |
| BMI = body mass index; BP= blood pressure; mmHg = millimeter of mercury; TIA = transient ischemic attack; HDL= high density lipoprotein; LDL= low density lipoprotein; eGFR = estimated Glomerular filtration rate. |

**Supplemental Table 2 A.** Univariable associations of quantified plaque characteristic with baseline characteristics.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **GLYC C** |  | **CD34** |  | **CD66b** |  | **CD68** |  | **SMA**  |  | **HE** |  | **EVG** |  |
|  | **Rho or mean(SD)** | **p** | **Rho or mean(SD)** | **p** | **Rho or mean(SD)** | **p** | **Rho or mean(SD)** | **p** | **Rho or mean(SD)** | **p** | **Rho or mean(SD)** | **p** | **Rho or mean(SD)** | **p** |
| **Hospital** |  | <0.001 |  | <0.001 |  | <0.001 |  | <0.001 |  | <0.001 |  | 0.002 |  | <0.001 |
| Sint. Antonius Nieuwegein | 0.27 (0.96) |  | 0.40 (0.89) |  | -0.30 (0.91) |  | -0.10 (0.90) |  | 0.12 (0.93) |  | -0.02 (1.00) |  | 0.26 (0.89) |  |
| UMC Utrecht, Utrecht | -0.04 (0.92) |  | -0.05 (0.88) |  | 0.32 (0.99) |  | 0.13 (1.07) |  | 0.13 (0.90) |  | 0.28 (0.98) |  | -0.09 (1.01) |  |
| **Date of surgery** | -0.229 | <0.001 | -0.354 | <0.001 | 0.007 | 0.83 | 0.052 | 0.03 | -0.104 | <0.001 | -0.163 | <0.001 | -0.009 | 0.72 |
| **Age (years)** | 0.037 | 0.18 | 0.021 | 0.44 | 0.066 | 0.03 | 0.089 | <0.001 | 0.006 | 0.81 | -0.005 | 0.84 | 0.013 | 0.58 |
| **Gender** |  | <0.001 |  | 0.09  |  | <0.001 |  | <0.001 |  | <0.001 |  | <0.001 |  | <0.001 |
| **Female** | -0.11 (0.92)  |  | 0.10 (0.90) |  | -0.27 (0.95) |  | -0.16 (0.99) |  | -0.10 (0.98) |  | -0.03 (0.98) |  | -0.05 (0.99) |  |
| **Male** | 0.19 (0.95) |  | 0.19 (0.92) |  | 0.12 (1.00) |  | 0.10 (0.99) |  | 0.11 (0.96) |  | 0.30 (0.91) |  | 0.13 (0.96) |  |
| **Systolic BP (mmHg)** | 0.012 | 0.67 | 0.040 | 0.18 | 0.048 | 0.15 | -0.009 | 0.73 | 0.015 | 0.56 | 0.004 | 0.89 | -0.002 | 0.93 |
| **Diastolic BP (mmHg)** | 0.036 | 0.21 | 0.038 | 0.20 | 0.078 | 0.02 | 0.024 | 0.34 | 0.036 | 0.15 | 0.036 | 0.19 | 0.043 | 0.09 |
| **Hypertension** |  | 0.10 |  | 0.04 |  | 0.19 |  | 0.62 |  | 0.67 |  | 0.38 |  | 0.04 |
| **Yes** | 0.13 (0.96) |  | 0.20 (0.90) |  | 0.03 (0.98) |  | 0.03 (0.99) |  | 0.05 (0.97) |  | 0.22 (0.93) |  | 0.10 (0.97) |  |
| **No** | 0.03 (0.90) |  | 0.08 (0.93) |  | -0.06 (1.06) |  | 0.00 (1.02) |  | 0.03 (0.97) |  | 0.17 (0.97) |  | -0.00 (0.96) |  |
| **Hypercholesterolemia** |  | 0.98 |  | 0.07  |  | 0.10  |  | 0.75  |  | 0.95 |  | 0.81 |  | 0.39 |
| **Yes** | 0.12 (0.95) |  | 0.15 (0.92) |  | 0.05 (1.02) |  | 0.01 (0.98) |  | 0.06 (0.97) |  | 0.21 (0.93) |  | 0.09 (0.98) |  |
| **No** | 0.12 (0.94) |  | 0.25 (0.90) |  | -0.07 (0.97) |  | 0.03 (1.04) |  | 0.06 (0.95) |  | 0.23 (0.93) |  | 0.05 (0.95) |  |
| **Smoking Status** |  | 0.08  |  | 0.35 |  | 0.29  |  | 0.05  |  | 0.54  |  | 0.73  |  | 0.09 |
| **Current smoker** | 0.15 (0.93) |  | 0.12 (0.90) |  | -0.01 (0.95) |  | -0.04 (1.00) |  | 0.07 (0.95) |  | 0.20 (0.94) |  | 0.09 (0.96) |  |
| **Ex-smoker** | 0.10 (0.98) |  | 0.19 (0.93) |  | 0.06 (1.05) |  | 0.09 (1.02) |  | 0.07 (0.96) |  | 0.22 (0.95) |  | 0.10 (0.99) |  |
| **Never smoked** | -0.03 (0.91) |  | 0.11 (0.92) |  | -0.08 (0.97) |  | -0.00 (0.96) |  | -0.00 (0.99) |  | 0.17 (0.93) |  | -0.05 (0.96) |  |
| **Total cholesterol (natural log transformed)**  | 0.025 | 0.46 | 0.058 | 0.08 | -0.071 | 0.06 | -0.100 | 0.001 | 0.002 | 0.95 | -0.013 | 0.68 | -0.010 | 0.75 |
| **LDL (natural log transformed)**  | -0.001 | 0.97 | 0.055 | 0.12 | -0.065 | 0.10 | -0.110 | <0.001 | 0.013 | 0.69 | -0.002 | 0.95 | 0.023 | 0.48 |
| **HDL (natural log transformed)**  | -0.036 | 0.30 | 0.030 | 0.39 | -0.097 | 0.01 | -0.078 | 0.01 | -0.027 | 0.38 | -0.048 | 0.15 | -0.069 | 0.03 |
| **Triglycerides (natural log transformed)**  | 0.008 | 0.82 | 0.000 | 0.99 | 0.005 | 0.90 | -0.016 | 0.60 | -0.024 | 0.45 | 0.022 | 0.51 | 0.001 | 0.98 |
| **BMI (natural log transformed)**  | 0.020 | 0.46 | -0.047 | 0.09 | 0.023 | 0.46 | 0.070 | 0.003 | 0.047 | 0.05 | 0.036 | 0.16 | 0.042 | 0.08 |
| **Kidney function (eGFR (mL/min/1.73 m²))** | 0.029 | 0.29 | 0.023 | 0.39 | -0.015 | 0.63 | -0.007 | 0.77 | 0.022 | 0.35 | -0.037 | 0.15 | 0.049 | 0.04 |
| **Diabetes mellitus** |  | 0.16 |  | 0.95 |  | 0.40 |  | 0.15 |  | 0.22  |  | 0.82 |  | 0.90  |
| **Yes** | 0.17 (0.97) |  | 0.17 (0.91) |  | -0.05 (0.89) |  | 0.08 (0.99) |  | -0.00 (0.96) |  | 0.19 (0.92) |  | 0.08 (0.99) |  |
| **No** | 0.08 (0.94) |  | 0.16 (0.92) |  | 0.02 (1.03) |  |  0.01 (1.00) |  | 0.06 (0.97) |  | 0.20 (0.95) |  | 0.07 (0.97) |  |
| **Use of statins** |  | 0.24 |  | 0.09 |  | 0.38  |  | 0.34 |  | 0.35 |  | 0.38 |  | 0.65 |
| **Yes** | 0.09 (0.96) |  | 0.14 (0.91) |  | 0.02 (1.01) |  | 0.04 (1.00) |  | 0.04 (0.97) |  | 0.19 (0.94) |  | 0.07 (0.97)  |  |
| **No** | 0.16 (0.92) |  | 0.25 (0.92) |  | -0.05 (0.95) |  | -0.02 (1.02) |  | 0.09 (0.96) |  | 0.24 (0.96) |  | 0.10 (0.96) |  |
| **Use of antihypertensive drugs** |  | 0.001 |  | 0.14 |  | 0.38 |  | 0.43 |  | 0.004 |  | 0.007 |  | 0.006 |
| **Yes** | 0.15 (0.96) |  | 0.18 (0.91) |  | 0.02 (0.98) |  | 0.03 (1.01) |  | 0.08 (0.96) |  | 0.24 (0.93) |  | 0.11 (0.97) |  |
| **No** | -0.05 (0.89) |  | 0.10 (0.95) |  | -0.05 (1.05) |  | -0.01 (0.96) |  | -0.07 (0.98) |  | 0.08 (0.99) |  | -0.04 (0.98) |  |
| **Use of antiplatelet drugs** |  | 0.56 |  | 0.70  |  | 0.99 |  | 0.76 |  | 0.40 |  | 0.22 |  | 0.14 |
| **Yes** | 0.11 (0.95) |  | 0.17 (0.91) |  | 0.00 (0.99)  |  | 0.02 (1.00) |  | 0.05 (0.97) |  | 0.21 (0.95) |  | 0.09 (0.97) |  |
| **No** | 0.06 (0.92) |  | 0.14 (0.94) |  | 0.00 (1.06) |  | 0.04 (1.00) |  | -0.01 (0.94) |  | 0.12 (0.86) |  | -0.02 (0.95) |  |
| **Use of oral anticoagulant drugs** |  | 0.31 |  | 0.007 |  | 0.50 |  | 0.35 |  | 0.20 |  | 0.78 |  | 0.42 |
| **Yes** | 0.17 (0.93) |  | 0.34 (0.94) |  | 0.06 (0.99) |  | 0.08 (1.02) |  | 0.12 (0.99) |  | 0.22 (0.87) |  | 0.12 (0.94) |  |
| **No** | 0.09 (0.95) |  | 0.14 (0.91) |  | -0.00 (1.00) |  | 0.02 (1.00) |  | 0.04 (0.96) |  | 0.20 (0.95) |  | 0.07 (0.98)  |  |
| **History of coronary artery disease** |  | 0.005 |  | 0.39 |  | 0.50 |  | 0.05 |  | 0.24 |  | 0.56 |  | 0.81 |
| **Yes** | 0.20 (0.97) |  | 0.20 (0.96) |  | 0.03 (0.99) |  | 0.09 (1.01) |  | 0.09 (0.96) |  | 0.22 (0.98) |  | 0.08 (0.98) |  |
| **No** | 0.05 (0.94) |  | 0.15 (0.89) |  | -0.01 (1.00) |  | -0.01 (1.00) |  | 0.03 (0.97) |  | 0.19 (0.93) |  | 0.07 (0.97) |  |
| **History of peripheral artery disease** |  | 0.32 |  | 0.56  |  | 0.73 |  | 0.16 |  | 0.30 |  | 0.23 |  | 0.78 |
| **Yes** | 0.15 (0.96) |  | 0.14 (0.95) |  | 0.02 (1.01) |  | -0.04 (1.04) |  | 0.00 (0.99) |  | 0.26 (0.95)  |  | 0.06 (1.02) |  |
| **No** | 0.09 (0.95) |  | 0.17 (0.91) |  | --0.00 (1.00) |  | 0.04 (0.99) |  | 0.06 (0.96) |  | 0.19 (0.94) |  | 0.08 (0.96) |  |
| **History of peripheral intervention(s)** |  | 0.63 |  | 0.10 |  | 0.13 |  | 0.25 |  | 0.10 |  | 0.22 |  | 0.02 |
| **Yes** | 0.08 (1.01) |  | 0.08 (0.94) |  | -0.09 (1.00) |  | -0.03 (1.02) |  | -0.03 (0.99) |  | 0.14 (0.96)  |  | -0.03 (1.01) |  |
| **No** | 0.11 (0.94) |  | 0.19 (0.91) |  | 0.03 (1.00) |  | 0.04 (1.00) |  | 0.07 (0.96) |  | 0.22 (0.94) |  | 0.10 (0.96) |  |
| **History of stroke or TIA** |  | 0.11  |  | 0.78 |  | 0.01 |  | 0.90  |  | 0.96  |  | 0.55 |  | 0.94 |
| **Yes** | 0.12 (0.95) |  | 0.17 (0.92) |  | 0.04 (1.00) |  | 0.02 (1.02) |  | 0.05 (0.98) |  | 0.19 (0.96) |  | 0.07 (0.96) |  |
| **No** | 0.02 (0.94) |  | 0.15 (0.89) |  | -0.15 (0.96) |  | 0.03 (0.92) |  | 0.05 (0.90) |  | 0.23 (0.89) |  | 0.08 (1.00) |  |
| **Ipsilateral stenosis**  |  | 0.03 |  | 0.008 |  | 0.19 |  | 0.83 |  | 0.02 |  | 0.08 |  | 0.43 |
| **0-50%** | 0.40 (0.66) |  | 0.34 (0.71) |  | 0.91 (0.63) |  | 0.02 (0.69) |  | -0.14 (1.38) |  | 0.99 (1.16) |  | -0.05 (0.90) |  |
| **50-70%** | -0.12 (0.98) |  | -0.11 (0.97) |  | -0.01 (1.04) |  | 0.07 (1.02) |  | -0.16 (0.86) |  | 0.11 (1.04) |  | -0.03 (1.05) |  |
| **70-99%** | 0.12 (0.94) |  | 0.19 (0.91) |  | -0.00 (1.00) |  | 0.01 (0.99) |  | 0.06 (0.97) |  | 0.21 (0.92) |  | 0.08 (0.96) |  |
| **Contralateral stenosis** |  | 0.30 |  | 0.86 |  | 0.09 |  | 0.49 |  | 0.28 |  | 0.06 |  | 0.55 |
| **0-50%** | 0.14 (0.96) |  | 0.20 (0.93) |  | 0.03 (0.99) |  | 0.00 (0.98) |  | 0.06 (0.96) |  | 0.24 (0.94)  |  | 0.05 (0.98) |  |
| **50-100%** | 0.09 (0.94) |  | 0.19 (0.90) |  | -0.08 (0.99)  |  | -0.03 (0.98) |  | 0.01 (0.97) |  | 0.15 (0.93) |  | 0.08 (0.92) |  |

**Supplemental Table 2 B and C.** Univariable associations of quantified plaque characteristic with baseline characteristics, sex stratified.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Male cohort** | **GLYC C** |  | **CD34** |  | **CD66b** |  | **CD68** |  | **SMA**  |  | **HE** |  | **EVG** |  |
|  | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** |
| **Hospital** |  | <0.001 |  | <0.001 |  | <0.001 |  | <0.001 |  | 0.002 |  | 0.01 |  | <0.001 |
| **Sint. Antonius Nieuwegein** | 0.37 |  | 0.44 |  | -0.18 |  | 0.00 |  | 0.20 |  | 0.23 |  | 0.35 |  |
| **UMC Utrecht, Utrecht** | 0.04 |  | -0.02 |  | 0.43 |  | 0.18 |  | 0.03 |  | 0.38 |  | -0.06 |  |
| **Date of surgery** | -0.229 | <0.001 | -0.354 | <0.001 | 0.007 | 0.83 | 0.052 | 0.03 | -0.104 | <0.001 | -0.163 | <0.001 | -0.009 | 0.72 |
| **Age (years)** | 0.037 | 0.18 | 0.021 | 0.44 | 0.066 | 0.03 | 0.089 | <0.001 | 0.006 | 0.81 | -0.005 | 0.84 | 0.013 | 0.58 |
| **Systolic BP (mmHg)** | 0.012 | 0.67 | 0.040 | 0.18 | 0.048 | 0.15 | -0.009 | 0.73 | 0.015 | 0.56 | 0.004 | 0.89 | -0.002 | 0.93 |
| **Diastolic BP (mmHg)** | 0.036 | 0.21 | 0.038 | 0.20 | 0.078 | 0.02 | 0.024 | 0.34 | 0.036 | 0.15 | 0.036 | 0.19 | 0.043 | 0.09 |
| **Hypertension** |  | 0.32 |  | 0.14 |  | 0.19 |  | 0.62 |  | 0.58 |  | 0.31 |  | 0.07 |
| **Yes** | 0.22 |  | 0.22 |  | 0.16 |  | 0.10 |  | 0.12 |  | 0.33 |  | 0.16 |  |
| **No** | 0.15 |  | 0.13 |  | 0.05 |  | 0.07 |  | 0.09 |  | 0.27 |  | 0.05 |  |
| **Hypercholesterolemia** |  | 0.61 |  | 0.24 |  | 0.19 |  | 0.35 |  | 0.62 |  | 0.58 |  | 0.79 |
| **Yes** | 0.20 |  | 0.18 |  | 0.16 |  | 0.07 |  | 0.11 |  | 0.31 |  | 0.14 |  |
| **No** | 0.23 |  | 0.26 |  | 0.06 |  | 0.13 |  | 0.14 |  | 0.34 |  | 0.12 |  |
| **Smoking Status** |  | 0.15 |  | 0.27 |  | 0.67 |  | 0.07 |  | 0.63 |  | 0.86 |  | 0.06 |
| **Current smoker** | 0.25 |  | 0.12 |  | 0.11 |  | 0.06 |  | 0.10 |  | 0.30 |  | 0.14 |  |
| **Ex-smoker** | 0.18 |  | 0.22 |  | 0.15 |  | 0.16 |  | 0.15 |  | 0.31 |  | 0.15 |  |
| **Never smoked** | 0.03 |  | 0.13 |  | 0.05 |  | -0.03 |  | 0.08 |  | 0.26 |  | -0.07 |  |
| **Total cholesterol (natural log transformed)**  | 0.025 | 0.46 | 0.058 | 0.08 | -0.071 | 0.06 | -0.100 | 0.001 | 0.002 | 0.95 | -0.013 | 0.68 | -0.010 | 0.75 |
| **LDL (natural log transformed)**  | -0.001 | 0.97 | 0.055 | 0.12 | -0.065 | 0.10 | -0.110 | <0.001 | 0.013 | 0.69 | -0.002 | 0.95 | 0.023 | 0.48 |
| **HDL (natural log transformed)**  | -0.036 | 0.30 | 0.030 | 0.39 | -0.097 | 0.01 | -0.078 | 0.01 | -0.027 | 0.38 | -0.048 | 0.15 | -0.069 | 0.03 |
| **Triglycerides (natural log transformed)**  | 0.008 | 0.82 | 0.000 | 0.99 | 0.005 | 0.90 | -0.016 | 0.60 | -0.024 | 0.45 | 0.022 | 0.51 | 0.001 | 0.98 |
| **BMI (natural log transformed)**  | 0.020 | 0.46 | -0.047 | 0.09 | 0.023 | 0.46 | 0.070 | 0.003 | 0.047 | 0.05 | 0.036 | 0.16 | 0.042 | 0.08 |
| **Kidney function (eGFR (mL/min/1.73 m²))** | 0.029 | 0.29 | 0.023 | 0.39 | -0.015 | 0.63 | -0.007 | 0.77 | 0.022 | 0.35 | -0.037 | 0.15 | 0.049 | 0.04 |
| **Diabetes mellitus** |  | 0.12 |  | 0.74 |  | 0.02 |  | 0.75 |  | 0.12 |  | 0.66 |  | 0.93 |
| **Yes** | 0.28 |  | 0.17 |  | -0.02 |  | 0.12 |  | 0.04 |  | 0.28 |  | 0.13 |  |
| **No** | 0.17 |  | 0.20 |  | 0.16 |  | 0.10 |  | 0.14 |  | 0.31 |  | 0.13 |  |
| **Use of statins** |  | 0.12 |  | 0.21 |  | 0.97 |  | 0.73 |  | 0.46 |  | 0.12 |  | 0.36 |
| **Yes** | 0.17 |  | 0.17 |  | 0.12 |  | 0.11 |  | 0.10 |  | 0.28 |  | 0.12 |  |
| **No** | 0.28 |  | 0.26 |  | 0.12 |  | 0.08 |  | 0.14 |  | 0.38 |  | 0.18 |  |
| **Use of antihypertensive drugs** |  | 0.01 |  | 0.44 |  | 0.76 |  | 0.85 |  | 0.01 |  | 0.07 |  | 0.05 |
| **Yes** | 0.24 |  | 0.20 |  | 0.13 |  | 0.11 |  | 0.15 |  | 0.33 |  | 0.16 |  |
| **No** | 0.06 |  | 0.15 |  | 0.10 |  | 0.09 |  | -0.02 |  | 0.21 |  | 0.03 |  |
| **Use of antiplatelet drugs** |  | 0.86 |  | 0.90 |  | 0.31 |  | 0.87 |  | 0.40 |  | 0.37 |  | 0.08 |
| **Yes** | 0.20 |  | 0.19 |  | 0.11 |  | 0.10 |  | 0.12 |  | 0.24 |  | 0.15 |  |
| **No** | 0.18 |  | 0.20 |  | 0.23 |  | 0.12 |  | 0.06 |  | 0.31 |  | 0.01 |  |
| **Use of oral anticoagulant drugs** |  | 0.24 |  | 0.02 |  | 0.50 |  | 0.58 |  | 0.16 |  | 0.75 |  | 0.98 |
| **Yes** | 0.29 |  | 0.37 |  | 0.19 |  | 0.14 |  | 0.21 |  | 0.28 |  | 0.13 |  |
| **No** | 0.18 |  | 0.16 |  | 0.11 |  | 0.10 |  | 0.10 |  | 0.31 |  | 0.13 |  |
| **History of coronary artery disease** |  | 0.03 |  | 0.21 |  | 0.68 |  | 0.08 |  | 0.27 |  | 0.69 |  | 0.85 |
| **Yes** | 0.28 |  | 0.24 |  | 0.14 |  | 0.17 |  | 0.15 |  | 0.32 |  | 0.14 |  |
| **No** | 0.14 |  | 0.16 |  | 0.11 |  | 0.07 |  | 0.09 |  | 0.30 |  | 0.12 |  |
| **History of peripheral artery disease** |  | 0.49 |  | 0.58 |  | 0.66 |  | 0.26 |  | 0.79 |  | 0.43 |  | 0.52 |
| **Yes** | 0.23 |  | 0.16 |  | 0.16 |  | 0.04 |  | 0.10 |  | 0.35 |  | 0.16 |  |
| **No** | 0.18 |  | 0.20 |  | 0.11 |  | 0.12 |  | 0.12 |  | 0.29 |  | 0.12 |  |
| **History of peripheral intervention(s)** |  | 0.68 |  | 0.30 |  | 0.18 |  | 0.28 |  | 0.28 |  | 0.20 |  | 0.09 |
| **Yes** | 0.17 |  | 0.13 |  | 0.01 |  | 0.04 |  | 0.05 |  | 0.23 |  | 0.02 |  |
| **No** | 0.20 |  | 0.21 |  | 0.15 |  | 0.12 |  | 0.13 |  | 0.32 |  | 0.15 |  |
| **History of stroke or TIA** |  | 0.25 |  | 0.99 |  | 0.07 |  | 0.85 |  | 0.56 |  | 0.71 |  | 0.76 |
| **Yes** | 0.21 |  | 0.19 |  | 0.15 |  | 0.11 |  | 0.12 |  | 0.30 |  | 0.13 |  |
| **No** | 0.12 |  | 0.19 |  | -0.01 |  | 0.09 |  | 0.08 |  | 0.32 |  | 0.11 |  |
| **Ipsilateral stenosis**  |  | 0.04 |  | <0.001 |  | 0.13 |  | 0.86 |  | 0.003 |  | 0.17 |  | 0.15 |
| **0-50%** | 0.18 |  | 0.08 |  | 1.17 |  | 0.05 |  | -0.14 |  | 0.99 |  | -0.29 |  |
| **50-70%** | -0.07 |  | -0.22 |  | 0.00 |  | 0.05 |  | -0.18 |  | 0.21 |  | -0.02 |  |
| **70-99%** | 0.22 |  | 0.23 |  | 0.13 |  | 0.10 |  | 0.14 |  | 0.32 |  | 0.14 |  |
| **Contralateral stenosis** |  | 0.49 |  | 0.62 |  | 0.33 |  | 0.77 |  | 0.74 |  | 0.91 |  | 0.03 |
| **0-50%** | 0.23 |  | 0.21 |  | 0.13 |  | 0.06 |  | 0.11 |  | 0.30 |  | 0.06 |  |
| **50-100%** | 0.18 |  | 0.24 |  | 0.06 |  | 0.08 |  | 0.09 |  | 0.30 |  | 0.18 |  |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Female cohort** | **GLYC C** |  | **CD34** |  | **CD66b** |  | **CD68** |  | **SMA**  |  | **HE** |  | **EVG** |  |
|  | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** | **Rho or mean** | **p** |
| **Hospital** |  | 0.002 |  | <0.001 |  | <0.001 |  | <0.001 |  | 0.31 |  | 0.24 |  | 0.006 |
| **Sint. Antonius Nieuwegein** | 0.03 |  | 0.31 |  | -0.56 |  | -0.31 |  | -0.06 |  | -0.08 |  | 0.07 |  |
| **UMC Utrecht, Utrecht** | -0.25 |  | -0.11 |  | 0.04 |  | 0.00 |  | -0.14 |  | 0.02 |  | -0.17 |  |
| **Date of surgery** | -0.229 | <0.001 | -0.354 | <0.001 | 0.007 | 0.83 | 0.052 | 0.03 | -0.104 | <0.001 | -0.163 | <0.001 | -0.009 | 0.72 |
| **Age (years)** | 0.037 | 0.18 | 0.021 | 0.44 | 0.066 | 0.03 | 0.089 | <0.001 | 0.006 | 0.81 | -0.005 | 0.84 | 0.013 | 0.58 |
| **Systolic BP (mmHg)** | 0.012 | 0.67 | 0.040 | 0.18 | 0.048 | 0.15 | -0.009 | 0.73 | 0.015 | 0.56 | 0.004 | 0.89 | -0.002 | 0.93 |
| **Diastolic BP (mmHg)** | 0.036 | 0.21 | 0.038 | 0.20 | 0.078 | 0.02 | 0.024 | 0.34 | 0.036 | 0.15 | 0.036 | 0.19 | 0.043 | 0.09 |
| **Hypertension** |  | 0.01 |  | 0.09 |  | 0.31 |  | 0.43 |  | 0.62 |  | 0.32 |  | 0.13 |
| **Yes** | -0.05 |  | 0.15 |  | -0.23 |  | -0.13 |  | -0.08 |  | 0.00 |  | -0.01 |  |
| **No** | -0.33 |  | -0.05 |  | -0.36 |  | -0.21 |  | -0.13 |  | -0.11 |  | -0.17 |  |
| **Hypercholesterolemia** |  | 0.35 |  | 0.13 |  | 0.21 |  | 0.40 |  | 0.41 |  | 0.64 |  | 0.22 |
| **Yes** | -0.05 |  | 0.09 |  | -0.22 |  | -0.13 |  | -0.06 |  | -0.01 |  | -0.01 |  |
| **No** | -0.15 |  | 0.23 |  | -0.36 |  | -0.21 |  | -0.13 |  | -0.06 |  | -0.13 |  |
| **Smoking Status** |  | 0.31 |  | 0.95 |  | 0.65 |  | 0.06 |  | 0.08 |  | 0.52 |  | 0.78 |
| **Current smoker** | -0.03 |  | 0.11 |  | -0.24 |  | -0.24 |  | 0.02 |  | 0.00 |  | 0.01 |  |
| **Ex-smoker** | -0.19 |  | 0.08 |  | -0.32 |  | -0.16 |  | -0.19 |  | -0.08 |  | -0.06 |  |
| **Never smoked** | -0.11 |  | 0.09 |  | -0.20 |  | 0.03 |  | -0.09 |  | 0.06 |  | -0.03 |  |
| **Total cholesterol (natural log transformed)**  | 0.025 | 0.46 | 0.058 | 0.08 | -0.071 | 0.06 | -0.100 | 0.001 | 0.002 | 0.95 | -0.013 | 0.68 | -0.010 | 0.75 |
| **LDL (natural log transformed)**  | -0.001 | 0.97 | 0.055 | 0.12 | -0.065 | 0.10 | -0.110 | <0.001 | 0.013 | 0.69 | -0.002 | 0.95 | 0.023 | 0.48 |
| **HDL (natural log transformed)**  | -0.036 | 0.30 | 0.030 | 0.39 | -0.097 | 0.01 | -0.078 | 0.01 | -0.027 | 0.38 | -0.048 | 0.15 | -0.069 | 0.03 |
| **Triglycerides (natural log transformed)**  | 0.008 | 0.82 | 0.000 | 0.99 | 0.005 | 0.90 | -0.016 | 0.60 | -0.024 | 0.45 | 0.022 | 0.51 | 0.001 | 0.98 |
| **BMI (natural log transformed)**  | 0.020 | 0.46 | -0.047 | 0.09 | 0.023 | 0.46 | 0.070 | 0.003 | 0.047 | 0.05 | 0.036 | 0.16 | 0.042 | 0.08 |
| **Kidney function (eGFR (mL/min/1.73 m²))** | 0.029 | 0.29 | 0.023 | 0.39 | -0.015 | 0.63 | -0.007 | 0.77 | 0.022 | 0.35 | -0.037 | 0.15 | 0.049 | 0.04 |
| **Diabetes mellitus** |  | 1.00 |  | 0.52 |  | 0.12 |  | 0.06 |  | 0.83 |  | 0.99 |  | 0.85 |
| **Yes** | -0.11 |  | 0.15 |  | -0.11 |  | -0.01 |  | -0.12 |  | -0.04 |  | -0.06 |  |
| **No** | -0.11 |  | 0.09 |  | -0.32 |  | -0.20 |  | -0.09 |  | -0.03 |  | -0.04 |  |
| **Use of statins** |  | 0.80 |  | 0.25 |  | 0.06 |  | 0.23 |  | 0.61 |  | 0.51 |  | 0.56 |
| **Yes** | -0.10 |  | 0.08 |  | -0.23 |  | -0.13 |  | -0.11 |  | -0.02 |  | -0.03 |  |
| **No** | -0.13 |  | 0.20 |  | -0.45 |  | -0.26 |  | -0.06 |  | -0.10 |  | -0.10 |  |
| **Use of antihypertensive drugs** |  | 0.03 |  | 0.20 |  | 0.34 |  | 0.28 |  | 0.24 |  | 0.05 |  | 0.07 |
| **Yes** | -0.05 |  | 0.14 |  | -0.25 |  | -0.14 |  | -0.07 |  | 0.02 |  | 0.00 |  |
| **No** | -0.28 |  | -0.01 |  | -0.36 |  | -0.23 |  | -0.19 |  | -0.19 |  | -0.19 |  |
| **Use of antiplatelet drugs** |  | 0.18 |  | 0.30 |  | 0.03 |  | 0.99 |  | 0.51 |  | 0.13 |  | 0.70 |
| **Yes** | -0.09 |  | 0.12 |  | -0.24 |  | -0.16 |  | -0.09 |  | -0.01 |  | -0.04 |  |
| **No** | -0.30 |  | -0.04 |  | -0.67 |  | -0.16 |  | -0.20 |  | -0.24 |  | -0.11 |  |
| **Use of oral anticoagulant drugs** |  | 0.64 |  | 0.28 |  | 0.54 |  | 0.69 |  | 0.73 |  | 0.66 |  | 0.20 |
| **Yes** | -0.17 |  | 0.25 |  | -0.37 |  | -0.10 |  | -0.15 |  | 0.03 |  | 0.12 |  |
| **No** | -0.10 |  | 0.09 |  | -0.26 |  | -0.17 |  | -0.10 |  | -0.04 |  | -0.06 |  |
| **History of coronary artery disease** |  | 0.72 |  | 0.38 |  | 0.38 |  | 0.75 |  | 0.62 |  | 0.43 |  | 0.48 |
| **Yes** | -0.08 |  | 0.04 |  | -0.36 |  | -0.18 |  | -0.13 |  | -0.10 |  | -0.10 |  |
| **No** | -0.12 |  | 0.13 |  | -0.25 |  | -0.15 |  | -0.08 |  | -0.02 |  | -0.03 |  |
| **History of peripheral artery disease** |  | 0.63 |  | 0.77 |  | 0.70 |  | 0.21 |  | 0.07 |  | 0.67 |  | 0.08 |
| **Yes** | -0.06 |  | 0.08 |  | -0.31 |  | -0.26 |  | -0.25 |  | 0.01 |  | -0.20 |  |
| **No** | -0.12 |  | 0.11 |  | -0.27 |  | -0.13 |  | -0.06 |  | -0.04 |  | -0.01 |  |
| **History of peripheral intervention(s)** |  | 0.96 |  | 0.20 |  | 0.79 |  | 0.76 |  | 0.26 |  | 0.92 |  | 0.22 |
| **Yes** | -0.11 |  | -0.02 |  | -0.30 |  | -0.18 |  | -0.19 |  | -0.04 |  | -0.14 |  |
| **No** | -0.11 |  | 0.14 |  | -0.27 |  | -0.15 |  | -0.07 |  | -0.03 |  | -0.02 |  |
| **History of stroke or TIA** |  | 0.22 |  | 0.63 |  | 0.07 |  | 0.69 |  | 0.39 |  | 0.63 |  | 0.60 |
| **Yes** | -0.09 |  | 0.11 |  | -0.23 |  | -0.16 |  | -0.12 |  | -0.04 |  | -0.06 |  |
| **No** | -0.22 |  | 0.06 |  | -0.45 |  | -0.12 |  | -0.03 |  | 0.01 |  | 0.00 |  |
| **Ipsilateral stenosis**  |  | 0.12 |  | 0.25 |  | 0.58 |  | 0.24 |  | 0.99 |  | 0.29 |  | 0.36 |
| **0-50%** | 0.94 |  | 1.41 |  | 0.15 |  | -0.10 |  | -0.15 |  | 1.00 |  | 0.95 |  |
| **50-70%** | -0.35 |  | 0.25 |  | -0.04 |  | 0.13 |  | -0.10 |  | -0.23 |  | -0.08 |  |
| **70-99%** | -0.10 |  | 0.09 |  | -0.28 |  | -0.17 |  | -0.09 |  | 0.02 |  | -0.05 |  |
| **Contralateral stenosis** |  | 0.21 |  | 0.27 |  | 0.02 |  | 0.05 |  | 0.09 |  | <0.001 |  | 0.02 |
| **0-50%** | -0.04 |  | 0.18 |  | -0.18 |  | -0.12 |  | -0.04 |  | 0.11 |  | 0.04 |  |
| **50-100%** | -0.16 |  | 0.08 |  | -0.45 |  | -0.30 |  | -0.19 |  | -0.24 |  | -0.17 |  |

**Supplemental Table 3.** Univariable and multivariable associations of the other plaque characteristics with pre-procedural neurological symptoms, as derived from logistic regression analyses. Model 1 is unadjusted; Model 2 is adjusted for plaque size and Model 3 is adjusted for plaque size and confounders (**Supplemental Table 4**). The plaque characteristics and plaque sizes are inverse rank transformed in all analyses.

|  |  |  |
| --- | --- | --- |
|  |  | Pre-procedural symptoms (asymptomatic versus symptomatic) |
|  |  | Model 1 | Model 2 | Model 3 |
|  |  | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value |
| CD34 |  |  |  |  |  |  |  |
|  | Full cohort | 0.91 (0.79-1.04) | 0.17 | 0.86 (0.75-1.00) | 0.04 | 0.99 (0.84-1.17) | 0.84 |
|  | Male | 0.91 (0.78-1.07) | 0.25 | 0.86 (0.73-1.02) | 0.08 | 0.94 (0.78-1.14) | 0.54 |
|  | Female | 0.93 (0.71-1.21) | 0.58 | 0.87 (0.67-1.15) | 0.33 | 1.16 (0.85-1.58) | 0.35 |
| CD66b |  |  |  |  |  |  |  |
|  | Full cohort | 1.19 (1.03-1.37) | 0.02 | 1.23 (1.06-1.42) | 0.007 | 1.23 (1.06-1.43) | 0.008 |
|  | Male | 1.22 (1.04-1.45) | 0.02 | 1.26 (1.06-1.49) | 0.009 | 1.25 (1.05-1.49) | 0.01 |
|  | Female | 1.20 (0.90-1.60) | 0.21 | 1.28 (0.94-1.73) | 0.12 | 1.22 (0.89-1.67) | 0.23 |
| CD68 |  |  |  |  |  |  |  |
|  | Full cohort | 1.03 (0.93-1.14) | 0.58 | 0.95 (0.75-1.20) | 0.65 | 1.06 (0.83-1.37) | 0.63 |
|  | Male | 1.03 (0.91-1.16) | 0.69 | 0.94 (0.71-1.23) | 0.63 | 0.92 (0.69-1.21) | 0.54 |
|  | Female | 1.11 (0.91-1.37) | 0.31 | 1.01 (0.64-1.57) | 0.98 | 0.87 (0.52-1.46) | 0.60 |
| SMA |  |  |  |  |  |  |  |
|  | Full cohort | 0.95 (0.85-1.06) | 0.37 | 0.92 (0.75-1.13) | 0.41 | 1.18 (0.93-1.49) | 0.16 |
|  | Male | 0.98 (0.86-1.12) | 0.75 | 0.92 (0.73-1.17) | 0.50 | 0.99 (0.77-1.28) | 0.96 |
|  | Female | 0.93 (0.76-1.14) | 0.49 | 0.93 (0.62-1.40) | 0.72 | 1.35 (0.84-2.16) | 0.21 |
| HE |  |  |  |  |  |  |  |
|  | Full cohort | 0.91 (0.81-1.03) | 0.13 | 0.92 (0.59-1.42) | 0.70 | 1.26 (0.79-2.01) | 0.34 |
|  | Male | 0.95 (0.82-1.10) | 0.50 | 0.98 (0.59-1.65) | 0.94 | 1.30 (0.76-2.23) | 0.33 |
|  | Female | 0.90 (0.71-1.13) | 0.35 | 0.93 (0.40-2.18) | 0.87 | 1.21 (0.48-3.06) | 0.69 |
| EvG |  |  |  |  |  |  |  |
|  | Full cohort | 0.94 (0.84-1.06) | 0.30 | 1.01 (0.88-1.16) | 0.92 | 0.96 (0.82-1.11) | 0.55 |
|  | Male | 0.96 (0.84-1.10) | 0.58 | 0.97 (0.82-1.14) | 0.69 | 0.93 (0.78-1.11) | 0.44 |
|  | Female | 0.93 (0.75-1.15) | 0.50 | 1.14 (0.87-1.5) | 0.35 | 1.06 (0.79-1.42) | 0.71 |

**Supplemental Table 4.** Overview of the confounders included in the final logistic regression models of the association between the quantified plaque characteristics and pre-procedural symptoms (asymptomatic versus symptomatic patients).

|  |  |  |
| --- | --- | --- |
|  |  | Potential confounders included in the final logistic regression models of the association between quantified plaque characteristics and pre-procedural symptoms |
| **Glycophorin C** |  |  |
|  | Full cohort | Plaque size, date of surgery, date of surgery, gender, smoking status, use of antihypertensive drugs and history of coronary artery disease  |
|  | Male | Plaque size, date of surgery, use of antihypertensive drugs and history of coronary artery disease |
|  | Female | Plaque size and date of surgery |
| **CD34** |  |  |
|  | Full cohort | Plaque size, type of WSI, date of surgery, gender, BMI (log transformed) and history of peripheral intervention(s) |
|  | Male | Plaque size, type of WSI, date of surgery and BMI (log transformed) |
|  | Female | Plaque size, date of surgery and total cholesterol levels (log transformed) |
| **CD66b** |  |  |
|  | Full cohort | Plaque size, age, gender and contralateral carotid stenosis grade  |
|  | Male | Plaque size and age |
|  | Female | Plaque size, age, total cholesterol levels (log transformed), use of antihypertensive drugs and contralateral carotid stenosis grade |
| **CD68** |  |  |
|  | Full cohort | Plaque size, type of WSI, date of surgery, age, gender, smoking status, BMI (log transformed) and history of coronary artery disease |
|  | Male | Plaque size, date of surgery, age, BMI (log transformed) and use of antihypertensive drugs |
|  | Female | Plaque size,date of surgery, age, total cholesterol levels (log transformed) and contralateral carotid stenosis grade |
| **SMA** |  |  |
|  | Full cohort | Plaque size, type of WSI, date of surgery, gender, BMI (log transformed), use of antihypertensive drugs and history of peripheral intervention(s) |
|  | Male | Plaque size, date of surgery, BMI (log transformed) and use of antihypertensive drugs |
|  | Female | Plaque size, date of surgery, smoking status, history of peripheral intervention(s) and contralateral carotid stenosis grade |
| **HE** |  |  |
|  | Full cohort | Plaque size, type of WSI, date of surgery, gender, use of antihypertensive drugs and contralateral carotid stenosis grade |
|  | Male | Plaque size, type of WSI, date of surgery and use of antihypertensive drugs |
|  | Female | Plaque size, type of WSI, date of surgery and contralateral carotid stenosis grade |
| **EvG** |  |  |
|  | Full cohort | Plaque size, type of WSI, gender, use of antihypertensive drugs, smoking status, BMI (log transformed), kidney function and history of peripheral intervention(s) |
|  | Male | Plaque size, type of WSI, use of antihypertensive drugs, BMI (log transformed), kidney function, history of peripheral intervention(s) and contralateral carotid stenosis grade |
|  | Female | Plaque size, type of WSI, history of peripheral intervention(s) and contralateral carotid stenosis grade |

**Supplemental Table 5.** Univariable and multivariable associations of quantified plaque characteristics with new major cardiovascular adverse events within 3-years after surgery, as derived from Cox regression analyses (Model 1: unadjusted, Model 2 adjusted for plaque size and Model 3 for plaque size and confounders (**Supplemental Table 6**). The quantified plaque characteristics and plaque sizes are inverse rank transformed in all analyses.

|  |  |  |
| --- | --- | --- |
|  |  | **MACE within a 3-year period after surgery** |
|  |  | **Model 1** | **Model 2** | **Model 3** |
|  |  | **events** | **HR (95% CI)** | **p** | **events**  | **HR (95% CI)** | **p** | **events**  | **HR (95% CI)** | **p** |
| **CD34** |  |  |  |  |  |  |  |  |  |  |
|  | Full cohort | 161 | 1.12 (0.95-1.33) | 0.18 | 161 | 1.11 (0.93-1.32) | 0.26 | 151 | 1.08 (0.90-1.29) | 0.43 |
|  | Male | 119 | 1.18 (0.97-1.44) | 0.09 | 119 | 1.19 (0.97-1.45) | 0.10 | 119 | 1.16 (0.95-1.42) | 0.16 |
|  | Female | 42 | 0.95 (0.67-1.35) | 0.76 | 42 | 0.91 (0.64-1.30) | 0.60 | 38 | 1.11 (0.72-1.70) | 0.63 |
| **CD66b** |  |  |  |  |  |  |  |  |  |  |
|  | Full cohort | 124 | 1.03 (0.86-1.23) | 0.78 | 124 | 1.10 (0.92-1.32) | 0.29 | 117 | 1.11 (0.92-1.35) | 0.29 |
|  | Male | 99 | 0.98 (0.80-1.20) | 0.85 | 99 | 1.04 (0.85-1.28) | 0.69 | 94 | 1.07 (0.86-1.33) | 0.54 |
|  | Female | 25 | 0.99 (0.63-1.54) | 0.96 | 25 | 1.13 (0.72-1.77) | 0.58 | 23 | 1.21 (0.71-2.05) | 0.46 |
| **CD68** |  |  |  |  |  |  |  |  |  |  |
|  | Full cohort | 227 | 0.98 (0.86-1.12) | 0.78 | 227 | 0.87 (0.66-1.16) | 0.35 | 210 | 0.88 (0.66-1.18) | 0.39 |
|  | Male | 168 | 0.99 (0.85-1.15) | 0.85 | 168 | 0.77 (0.56-1.07) | 0.12 | 156 | 0.83 (0.59-1.15) | 0.26 |
|  | Female | 59 | 0.93 (0.72-1.21) | 0.58 | 59 | 1.25 (0.70-2.21) | 0.44 | 54 | 0.96 (0.54-1.72) | 0.71 |
| **SMA** |  |  |  |  |  |  |  |  |  |  |
|  | Full cohort | 226 | 0.94 (0.82-1.07) | 0.33 | 226 | 0.89 (0.69-1.16) | 0.40 | 226 | 0.88 (0.68-1.13) | 0.32 |
|  | Male | 167 | 0.97 (0.83-1.14) | 0.71 | 167 | 0.84 (0.63-1.14) | 0.26 | 167 | 0.83 (0.61-1.12) | 0.23 |
|  | Female | 59 | 0.81 (0.62-1.06) | 0.12 | 59 | 1.15 (0.67-1.98) | 0.62 | 58 | 1.16 (0.69-1.95) | 0.58 |
| **HE** |  |  |  |  |  |  |  |  |  |  |
|  | Full cohort | 184 | 1.07 (0.91-1.25) | 0.42 | 184 | 0.82 (0.48-1.40) | 0.46 | 180 | 0.86 (0.49-1.49) | 0.58 |
|  | Male | 134 | 1.10 (0.91-1.33) | 0.31 | 134 | 0.91 (0.48-1.71) | 0.76 | 133 | 0.94 (0.50-1.78) | 0.89 |
|  | Female | 50 | 0.95 (0.70-1.28) | 0.72 | 50 | 0.58 (0.20-1.67) | 0.31 | 48 | 0.86 (0.27-2.69) | 0.78 |
| **EvG** |  |  |  |  |  |  |  |  |  |  |
|  | Full cohort | 216 | 1.15 (1.00-1.32) | 0.04 | 216 | 1.21 (1.00-1.46) | 0.046 | 205 | 1.28 (1.05-1.56) | 0.02 |
|  | Male | 159 | 1.21 (1.03-1.43) | 0.02 | 159 | 1.21 (0.98-1.45) | 0.08 | 145 | 1.32 (1.05-1.67) | 0.02 |
|  | Female | 57 | 0.99 (0.76-1.30) | 0.95 | 57 | 1.27 (0.83-1.95) | 0.26 | 55 | 1.35 (0.88-2.06) | 0.17 |

**Supplemental Table 6.** Overview of potential confounders included in the final cox regression models of the associations between quantified plaque characteristics and MACE.

|  |  |  |
| --- | --- | --- |
|  |  | Potential confounders included in the final MACE models per plaque characteristic. |
| **Glycophorin C** |  |  |
|  | Full cohort | Plaque size, gender, hypertension, smoking status and history of coronary artery disease |
|  | Male | Plaque size, use of antihypertensive drugs, history of coronary artery disease |
|  | Female | Plaque size, hospital, date of surgery and use of antihypertensive drugs |
| **CD34** |  |  |
|  | Full cohort | Plaque size, gender, hypertension, total cholesterol (log transformed), use of anticoagulant drugs and history peripheral intervention(s) |
|  | Male | Plaque size and use of oral anticoagulants |
|  | Female | Plaque size, hospital, date of surgery, hypertension, total cholesterol (log transformed) and BMI (log transformed) |
| **CD66b** |  |  |
|  | Full cohort | Plaque size, age, gender, total cholesterol (log transformed), HDL (log transformed) and contralateral carotid stenosis grade |
|  | Male | Plaque size, age, HDL (log transformed) and history of diabetes |
|  | Female | Plaque size, hospital, total cholesterol (log transformed), HDL (log transformed) and contralateral carotid stenosis grade |
| **CD68** |  |  |
|  | Full cohort | Plaque size, age, gender, smoking status, total cholesterol (log transformed), HDL (log transformed) and history of coronary artery disease |
|  | Male | Plaque size, age, HDL (log transformed), smoking status and history of coronary artery disease |
|  | Female | Plaque size, hospital, date of surgery, total cholesterol (log transformed), HDL (log transformed), BMI (log transformed), history of diabetes and contralateral carotid stenosis grade |
| **SMA** |  |  |
|  | Full cohort | Plaque size, gender, use of antihypertensive drugs and history of peripheral intervention(s) |
|  | Male | Plaque size and use of antihypertensive drugs |
|  | Female | Plaque size, date of surgery, BMI (log transformed) and contralateral carotid stenosis grade |
| **HE** |  |  |
|  | Full cohort | Plaque size, gender, use of antihypertensive drugs and contralateral carotid stenosis grade |
|  | Male | Plaque size and use of antihypertensive drugs |
|  | Female | Plaque size, date of surgery, use of antihypertensive drugs and contralateral carotid stenosis grade |
| **EvG** |  |  |
|  | Full cohort | Plaque size, gender, HDL (log transformed), use of antihypertensive drugs, kidney function and history of peripheral intervention(s) |
|  | Male | Plaque size, smoking status, HDL (log transformed), kidney function, use of antihypertensive drugs, use of any antiplatelet drug, history of peripheral intervention(s) and contralateral carotid stenosis grade |
|  | Female | Plaque size, hospital, BMI (log transformed), kidney function, use of antihypertensive drugs and contralateral carotid stenosis grade |

**Supplemental results**

**Associations of other quantified (extra)cellular plaque characteristics, measured by the** slideToolkit **method, with symptoms and outcomes**

We also explored the association between other quantified plaque characteristics and symptoms as well as outcomes (**Supplemental Table 3 and 5**). In contrast to glycophorin C, quantified CD34 levels adjusted for plaque size were associated with lower odds for pre-procedural neurological symptoms (Model 2: OR 0.86, 95%CI 0.75-1.00, p=0.04), however the association disappeared when we corrected for additional confounders (**Supplemental Table 3 and 4)**. The association of quantified CD66b was similar to glycophorin C: unadjusted CD66b was associated with pre-procedural neurological symptoms (Model 1: OR: 1.19, 95%CI:1.03-1.37, p=0.02) (**Supplemental Table 3**). After adjustment for plaque size and confounders (**Supplemental Table 4**), CD66b remained associated with pre-procedural neurological symptoms independent of potential confounders (Model 3 OR: 1.23, 95%CI: 1.06-1.43, p=0.008) (**Supplemental Table 3**). In the sex stratified analysis CD66b was also independently associated with pre-procedural neurological symptoms in males but not in females (Model 3: OR 1.25; 95%CI 1.05-1.49, p=0.01 and model 3: OR1.22, 95%CI 0.89-1.67, p=0.23, for males and females respectively) (**Supplemental Table 4**). Yet, we found no association between CD66b and outcomes during three years follow-up in either males or females (**Supplemental Table 5**). In contrast, EVG was found to be independently associated with a higher risk for MACE within 3-years after surgery in the full cohort but also for males only in the sex stratified analysis (Model 3: HR 1.28, 95%CI 1.05-1.56, p=0.02 and Model 3: HR 1.32, 95%CI 1.05-1.67, p=0.02, for the full cohort and males separately, respectively) (**Supplemental Table 5**).